Review Article
J Integral Sci, 2025, Volume 8, Issue 2, 24-29

Journal of Integral Sciences [JIS]
[An International Open Access Journal]
Available at www.jisciences.com ISSN: 2581-5679

AI IN THERAPEUTIC TARGETING: REDEFINING DRUG DELIVERY THROUGH SMART SYSTEMS

Majji Murali Krishna[1], Umme Kulsum[1], Arshiya Aqsa Syed[1], Challa Maruthi Santhosh[1], A. Suneetha[1], Patibandla Jahnavi[1*]

KVSR Siddartha College of Pharmaceutical Sciences, Vijayawada, Andhra Pradesh, India.

Received: 04 June 2025 Revised: 17 June 2025 Accepted: 06 July 2025

Abstract
The fusion of Artificial Intelligence (AI) with modern drug delivery systems marks a pivotal shift in the way therapeutics are designed, administered, and monitored. Traditional drug delivery platforms have long struggled with issues like off-target effects, variable bioavailability, and poor patient adherence. Smart drug delivery systems aim to overcome these limitations by responding to internal or external physiological stimuli-offering precise, targeted, and often self-regulated release of medications. When integrated with AI, these systems gain further intelligence: enabling real-time decision-making, predicting release kinetics, optimizing formulations, and personalizing dosing strategies. This review explores the evolving landscape of AI-assisted smart drug delivery systems, highlighting how machine learning, deep learning, and predictive analytics are redefining the design and deployment of nanocarriers, wearable devices, and hybrid platforms. Special focus is given to AI's role in material selection, pharmacogenomics, patient stratification, and theranostics. We also address critical challenges related to data privacy, regulatory ambiguity, algorithmic transparency, and ethical accountability. Moreover, emerging opportunities such as digital twins, closed-loop systems, and open-source AI platforms are discussed for their transformative potential. Together, AI and smart delivery platforms offer a promising vision of personalized, adaptive, and data-driven healthcare. As innovation continues to bridge computation with clinical application, the next generation of therapeutics may be as intelligent as they are effective-heralding a future where precision medicine is not just ideal, but inevitable.

Keywords: Smart drug delivery systems, Artificial intelligence, Precision targeting, Pharmacogenomics, Theranostics, Nanocarriers, Personalized medicine, AI-enabled dosing, Deep learning, Closed-loop systems.

***Corresponding Author**
Patibandla Jahnavi

DOI: https://doi.org/10.37022/jis.v8i2.107

Produced and Published by
South Asian Academic Publications

Introduction
Drug delivery has long stood as a central challenge in modern medicine. While scientific advancements have introduced powerful new molecules and biologics, their therapeutic success still heavily depends on how effectively they are delivered to the intended site of action. Conventional drug delivery systems often fall short-suffering from poor bioavailability, systemic side effects, off-target accumulation, and lack of adaptability to dynamic biological environments. Especially in complex diseases like cancer, neurodegenerative disorders, and autoimmune conditions, there remains a persistent need for smarter, more precise delivery platforms [1,2].

Amid these challenges, Artificial Intelligence (AI) is emerging as a revolutionary tool in healthcare, with growing applications across diagnostics, imaging, drug discovery, and now, drug delivery. AI technologies—particularly machine learning (ML), deep learning (DL), and natural language processing (NLP)—offer unprecedented capabilities in analyzing vast datasets, recognizing patterns, and predicting outcomes. In the realm of drug delivery, AI enables us to design more efficient delivery vehicles, simulate release kinetics, and even personalize treatment regimens based on patient-specific parameters [3]. The concept of "smart systems" in drug delivery refers to platforms that can sense, respond, and adapt to physiological cues-such as pH, temperature, enzymes, or glucose levels-in real time. These systems go beyond passive delivery, providing controlled, targeted, and often programmable release of therapeutic agents. When paired with AI, smart delivery systems can become truly intelligent, capable of optimizing therapeutic outcomes while minimizing side effects [3,4].

This review aims to explore the intersection of AI and drug delivery, focusing on how smart systems are being transformed by data-driven design, real-time feedback mechanisms, and predictive algorithms. By highlighting recent advances, real-world applications, and future prospects, this article seeks to provide a roadmap for the next generation of therapeutic strategies where precision meets adaptability through artificial intelligence.

The Role of AI in Modern Drug Discovery and Development

Drug discovery has historically been a long, expensive, and often uncertain journey-typically requiring over a decade and billions of dollars to bring a single successful drug to market. From identifying a promising biological target to screening thousands of compounds and optimizing lead candidates, each step is fraught with complexity. Artificial Intelligence (AI) has emerged as a powerful catalyst in this process, offering tools that can significantly accelerate, de-risk, and refine the way we discover and develop new therapeutics.

One of the earliest and most impactful contributions of AI is in target identification and validation. By mining vast biological and genomic datasets, AI algorithms can pinpoint disease-relevant genes, proteins, and pathways that might otherwise go unnoticed. These systems can analyze complex networks of gene expression, protein-protein interactions, and clinical data to prioritize the most promising therapeutic targets-something that would be impossible at this scale using traditional methods alone [5].

Once potential targets are identified, machine learning (ML) and deep learning (DL) models take center stage in compound screening. Instead of physically testing thousands or millions of molecules in wet labs, AI can predict the activity of compounds against a target using virtual screening. These models learn from historical bioactivity data to recognize which chemical structures are likely to bind effectively, saving valuable time and resources. DL architectures, particularly convolutional and graph neural networks, have proven especially effective in learning molecular fingerprints and predicting drug-likeness [6].

Another transformative application of AI is in forecasting ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of drug candidates. Predictive models can evaluate how a drug will behave in the human body-long before it reaches clinical trials. This enables early filtering of compounds that may have poor bioavailability, accumulate in off-target tissues, or cause organ toxicity. Such foresight reduces late-stage failures, improves safety, and enhances patient outcomes [7].

Perhaps one of the most game-changing advantages of AI is its ability to compress the drug development timeline. Traditional pipelines often rely on trial-and-error approaches, which are slow and costly. In contrast, AI-powered workflows can integrate predictive modeling, automated synthesis planning, and real-time data analysis, allowing researchers to iterate and optimize rapidly. With the integration of AI, companies have already begun to report faster identification of viable leads and more efficient progression from bench to bedside [8].

Smart Drug Delivery Systems: Concepts and Classifications

Traditional drug delivery methods often follow a one-size-fits-all approach—passively releasing medication into the body, regardless of timing, location, or need. While effective in some instances, this can result in fluctuating drug levels, unwanted side effects, and even drug resistance over time. To overcome these limitations, researchers have pioneered a new era of smart drug delivery systems-platforms that do more than deliver drugs; they think, sense, and respond [9].

At the heart of these systems lies a revolutionary idea: drug carriers that respond intelligently to physiological cues, releasing their cargo only when and where it's truly needed. These smart platforms don't just passively carry a drug; they actively participate in therapy. Whether triggered by a drop in pH, a rise in temperature, or a burst of specific enzymes, smart delivery systems offer precision, control, and adaptability—traits that align closely with the vision of personalized medicine. With the advent of artificial intelligence (AI), these systems are evolving even further, gaining the ability to learn from real-time data and tailor therapy dynamically to the patient's condition [10].

Smart drug delivery technologies can be classified based on the nature of stimuli they respond to and the form in which they are applied [11-15]:

1. Stimuli-Responsive Systems

These systems are designed to sense and react to subtle biological changes within the body, triggering drug release with remarkable specificity:

- **pH-responsive systems** take advantage of the acidic environment found in tumor tissues or inflamed areas, ensuring localized drug release where it's most needed.
- **Temperature-sensitive systems** respond to elevated temperatures in diseased tissues, such as infections or tumors, to deliver medication more precisely.
- **Enzyme-responsive systems** are activated by disease-specific enzymes, making them particularly promising for conditions like cancer or inflammatory disorders.
- **Redox-responsive systems** respond to oxidative stress-a hallmark of many pathological conditions—by releasing drugs when high levels of reactive oxygen species are detected.

2. Nanoparticle-Based Systems

Nanotechnology has unlocked a vast toolbox for smart drug delivery, offering platforms that are small, adaptable, and functional:

- **Liposomes** are biocompatible spherical vesicles capable of carrying both water- and fat-soluble drugs.
- **Polymeric nanoparticles** allow for fine-tuned, sustained, and targeted release, often using biodegradable materials.
- **Dendrimers**, with their tree-like branching structures, offer high drug-loading capacity and precise surface modifications.
- **Solid lipid nanoparticles** and **nanostructured lipid carriers (NLCs)** are especially useful for delivering poorly water-soluble drugs, enhancing stability and controlled release.

3. Implantable and Wearable Devices

These devices bring together engineering and medicine to create real-time, adaptive drug delivery systems:

- **Implantable microchips** can store and release medication on command, useful in conditions like cancer where dosing precision is crucial.
- **Wearable insulin patches**, integrated with glucose sensors, automatically adjust insulin release based on real-time blood sugar readings.
- **AI-powered infusion pumps** monitor physiological data and autonomously adjust dosage, reducing the risk of over- or under-dosing.

4. Hybrid Systems

Some of the most promising advancements involve combining multiple smart features into hybrid systems. Imagine nanoparticles that are magnetically guided to a tumor site and only release their drug payload when encountering tumor-specific enzymes. These systems integrate physical and biochemical triggers to deliver multi-layered control and enhance therapeutic accuracy.



Figure 01: Classifications of Smart Drug Delivery Systems

Integration of AI in Smart Drug Delivery Design

In today's era of precision medicine, artificial intelligence (AI) is more than just a buzzword-it's a powerful ally in reimagining how we design and deliver drugs. Gone are the days of trial-and-error; with AI, we can now predict, personalize, and perfect drug delivery platforms with remarkable accuracy. AI tools are helping researchers select the right materials and optimize formulations by analyzing large datasets that would be impossible to process manually. Through deep learning, scientists can forecast how a drug will behave over time—its release kinetics, stability, and how it might interact with the body. More impressively, AI plays a hands-on role in designing nanocarriers like liposomes, dendrimers, and micelles, adjusting their properties for targeted delivery. Even more futuristic are generative AI models that can dream up entirely new smart carriers tailored to respond to specific physiological conditions. This blend of computational intelligence with pharmaceutical science is truly transforming the future of therapy-making drug delivery not just smarter, but more human-centric [16-19].

Table 01: AI Supports Smart Drug Delivery Systems

AI Application Area	Description	Example Use
Material Selection & Formulation	AI analyzes vast datasets to identify the best combinations of excipients and delivery vehicles	Choosing optimal polymers for nanoparticles
Release Kinetics & Stability	Deep learning predicts drug release rates and shelf-life under different conditions	Forecasting drug stability in storage or in the body
Nanocarrier Design	AI helps fine-tune the properties of nanosystems like liposomes or dendrimers	Customizing liposome size and charge for cancer targeting
Generative Models	AI designs novel responsive carriers based on target parameters	Creating smart micelles that respond to pH or temperature changes

AI-Enabled Precision Targeting and Personalization

Artificial intelligence is redefining what it means to deliver the *right drug to the right patient at the right time*. In the realm of precision targeting, AI helps stratify patients based on their unique biological signatures—analyzing biomarkers, genetic profiles, and disease patterns to ensure treatments are tailored, not generalized. This allows for more effective, targeted therapy with fewer side effects. Coupled with AI-integrated diagnostics, such as imaging or biosensing technologies, we now have systems that can both diagnose and treat—ushering in the era of theranostics. AI also powers wearable technologies and biosensors, providing real-time feedback on patient responses, vital signs, and drug levels, enabling dose adjustments on the fly. Furthermore, through pharmacogenomics, AI can predict how an individual's genes may influence drug metabolism and efficacy, helping clinicians craft truly personalized dosing regimens. Altogether, these innovations make treatment not only smarter-but safer, more responsive, and uniquely tailored to each individual [20-24].

Table 02: AI in Precision Targeting and Personalized Smart Drug Delivery

AI Application Area	Functionality	Example
Patient Stratification	Identifies subgroups based on biomarkers or genetic data	Selecting patients for HER2-targeted breast cancer therapy
AI-Driven Theranostics	Combines diagnosis and therapy in a single platform	AI-assisted imaging guiding nanoparticle drug delivery
Wearables & Biosensors	Monitors vitals and adjusts drug delivery in real time	Smart insulin patches that respond to glucose fluctuations
Pharmacogenomics & AI Dosing	Personalizes dosing based on genetic metabolism profiles	AI-based warfarin dose prediction based on CYP2C9/ VKORC1 genes



Figure 02: AI-Enabled Precision Targeting and Personalization

Ethical, Regulatory, and Data Challenges

While AI has shown extraordinary potential in redefining drug delivery and therapeutics, it also brings a complex set of ethical, regulatory, and data governance challenges that must be addressed to ensure safe and equitable integration into healthcare systems.

One of the foremost concerns is data privacy and security. AI-driven therapeutic platforms depend heavily on access to large volumes of patient data-genomic sequences, health records, sensor feedback, and even behavioral data. Ensuring the confidentiality and integrity of this information is crucial. The risk of data breaches or misuse-especially when handled by third-party platforms-poses a significant threat to patient trust. Compliance with regulations like HIPAA (Health Insurance Portability and Accountability Act), GDPR (General Data Protection Regulation), and local data protection laws is essential, but enforcement and clarity around AI-specific contexts remain evolving[25,26].

The regulatory landscape for AI-based therapeutics and drug delivery devices is still emerging. Traditional frameworks, such as those used by the FDA, EMA, and CDSCO, were designed for physical products and drugs—not self-learning systems that adapt over time. Determining what constitutes "safety" and "efficacy" in a continuously evolving algorithm is a challenge regulators are only beginning to tackle. There is growing interest in "regulation by design," where explainability, accountability, and traceability are built into AI systems from the start.

Interpretability and reproducibility are also major scientific and ethical concerns. Many AI models—especially deep learning algorithms—are often labeled "black boxes" because their internal decision-making processes are difficult to understand or explain, even by their developers. In medicine, where decisions impact human lives, transparency is non-negotiable. Clinicians and patients need to know *why* a system recommends a specific dose or delivery method. Additionally, AI models must be reproducible across different populations and datasets to avoid bias, especially in global healthcare settings [27-29].

Ethically, the rise of AI in decision-making challenges traditional medical principles. What happens when a machine makes an incorrect dosing recommendation? Who is held accountable—the algorithm, the developer, or the physician? Moreover, if AI systems are trained on biased or incomplete datasets, they risk reinforcing health disparities rather than correcting them. These issues highlight the need for human oversight, ethical auditing, and inclusive datasets to ensure fair and safe development [30,31].

Future Trends and Opportunities

The future of smart drug delivery is rapidly evolving into a seamless blend of AI, robotics, synthetic biology, and digital twin technology—creating systems that are not only intelligent but also deeply personalized. Imagine a world where a virtual twin of a patient helps simulate treatment outcomes before a single dose is given, or where bioengineered carriers respond to inflammation or glucose levels in real time. With AI guiding closed-loop systems, chronic diseases like diabetes and epilepsy can be managed through continuous feedback-where sensors, analytics, and drug reservoirs talk to each other to deliver just the right amount of medication. These innovations shift us away from rigid regimens toward adaptive, self-regulating therapies. Even more exciting is the rise of open-source AI platforms, where global collaboration is breaking barriers of cost and access. In this emerging landscape, smart drug delivery is no longer just about automation-it's about building collaborative, learning systems that empower patients and transform care delivery on a global scale.

Conclusion

Artificial Intelligence is no longer a futuristic concept in healthcare-it is a present-day enabler of smarter, more responsive, and personalized drug delivery. By embedding intelligence into therapeutic platforms, AI allows us to transcend the limitations of conventional drug systems, offering controlled, stimulus-sensitive, and patient-tailored interventions. From predictive modelling and nanocarrier design to AI-guided dosing and real-time feedback integration, this synergy brings forth a new paradigm in treatment accuracy and safety. Despite challenges such as regulatory oversight, data security, and algorithmic bias, the path forward is filled with promise. Future advancements like digital twins, biosensor-embedded wearables, and collaborative AI ecosystems will further accelerate this evolution. Ultimately, the integration of AI into smart drug delivery represents not just technological innovation, but a profound shift toward human-centered, data-driven therapeutic care—where every treatment is as unique and intelligent as the patient receiving it.

Funding

Nil

Conflict of Interest

Authors are declared that no conflict of interest.

Acknowledgement

Not Declared

Informed Consent and Ethical Statement

Not Applicable

Author Contributions

Majji Murali Krishna, Umme Kulsum, Arshiya Aqsa Syed, and Challa Maruthi Santhosh contributed to literature review and manuscript writing. A. Suneetha assisted in technical editing and content refinement. Patibandla Jahnavi conceptualized, supervised, and finalized the manuscript.

References

1. Langer R. Drug delivery and targeting. Nature. 1998;392(6679 Suppl):5–10.
2. Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014;190:3–8.
3. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–9.
4. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–27.
5. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–87.
6. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
7. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133–49.
8. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377–97.
9. Gao W, Thamphiwatana S, Angsantikul P, Zhang L. Nanoparticle approaches against bacterial infections. Wiley Interdiscip Rev NanomedNanobiotechnol. 2014;6(6):532–47.
10. Peppas NA, Langer R. New challenges in biomaterials. Science. 1994;263(5154):1715–20.
11. Yu M, Wu J, Shi J, Farokhzad OC. Nanotechnology for protein delivery: overview and perspectives. J Control Release. 2016;240:24–37.
12. Mohanraj VJ, Chen Y. Nanoparticles – a review. Trop J Pharm Res. 2006;5(1):561–73.
13. Boehm K, McCracken N, Dew K. Theranostics: merging imaging and therapy. Radiol Technol. 2017;89(2):127–40.
14. Lee JH, Yigit MV, Mazumdar D, Lu Y. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Adv Drug Deliv Rev. 2010;62(6):592–605.
15. De M, Ghosh PS, Rotello VM. Applications of nanoparticles in biology. Adv Mater. 2008;20(22):4225–31.
16. Yang G, Phua SZF, Bindra AK, Zhao Y. Degradability and clearance of inorganic nanoparticles for biomedical applications. Adv Mater. 2019;31(10):e1805730.
17. Kim J, Park JY, Lee SB. Applications of smart nanomaterials in drug delivery and diagnostics. Adv Mater. 2020;32(15):e1804827.

18. Obermeyer AC, Swager TM. Functional materials for biomedical applications: smart design for targeted therapy. Acc Chem Res. 2017;50(4):822–30.
19. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.
20. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24–9.
21. Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230–43.
22. Ching T, Himmelstein DS, Beaulieu-Jones BK, Kalinin AA, Do BT, Way GP, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.
23. Bibault JE, Giraud P, Burgun A. Big data and machine learning in radiation oncology: state of the art and future prospects. Cancer Lett. 2016;382(1):110–7.
24. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med. 2019;380(14):1347–58.
25. Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst. 2014;2(1):3.
26. Zhou LQ, Wang JY, Yu SY, Wu GG, Wei Q, Deng YB, et al. Artificial intelligence in medical imaging of the liver. World J Gastroenterol. 2019;25(6):672–82.
27. Nour M, Caggiano V, Alqudah AM, Sacco E. AI applications for drug discovery and precision medicine. ComputBiol Med. 2021;133:104365.
28. Gao Y, Zhan M, Chen Y, Li G, Wang J. Intelligent nanocarriers for controlled drug delivery in cancer therapy. J Nanobiotechnology. 2022;20(1):30.
29. Zhang Y, Tang L, Zhang L, Hou M, Li Y. Advances in smart biomaterials for personalized drug delivery. J Mater Chem B. 2021;9(15):3100–14.
30. Subramanian S, Simonovsky M, Bujold KE, Tzeng SY, Green JJ. Artificial intelligence in the design of nanomedicine. Nat Rev Mater. 2022;7(5):328–41.
31. Sarker IH. AI-based modeling for COVID-19 pandemic prediction and response: challenges, opportunities, and future directions. J Biomed Inform. 2021;122:103996.